Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
- Author(s)
- Lew, TE; Casan, J; Bennett, R; Lin, VS; Whitechurch, A; Handunnetti, SM; Marlton, P; Shen, Y; Mulligan, SP; Blombery, P; Tam, CS; Roberts, AW; Seymour, JF; Thompson, PA; Anderson, MA;
- Details
- Publication Year 2024-03-26,Volume 8,Issue #6,Page 1439-1443
- Journal Title
- Blood Advances
- Publisher
- ASH
- Keywords
- Humans; Rituximab/therapeutic use; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Neoplasm Recurrence, Local; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use; *Sulfonamides
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 38231032
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2023011327
- Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2023011327- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-01-25 09:18:02
Last Modified: 2024-06-28 03:08:40